Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
Work
Year: 2018
Type: article
Abstract: Patients who have residual invasive breast cancer after receiving neoadjuvant chemotherapy plus human epidermal growth factor receptor 2 (HER2)–targeted therapy have a worse prognosis than those who h... more
Source: New England Journal of Medicine
Authors Gϋnter von Minckwitz, Chiun‐Sheng Huang, Max S. Mano, Sibylle Loibl, Eleftherios P. Mamounas +24 more
Institutions German Breast group, National Taiwan University Hospital, Instituto do Câncer do Estado de São Paulo, Cardiovascular Center Bethanien, Orlando Health +32 more
Cites: 24
Cited by: 2,136
Related to: 10
FWCI: 92.83
Citation percentile (by year/subfield): 100
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: bronze
Funder Genentech